“GvHD affects approximately 30,000 Americans and oral GvHD causes significant oral pain and discomfort, making it difficult for patients to eat, drink and speak. Oral GvHD is a great unmet need in cancer survivors.” Dr. Michael Chancellor, Chief Medical Officer at Lipella Pharmaceuticals Pittsburgh, PA, November 10, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), has received Orphan Drug Designation for its LP-310 drug candidate for oral...
![Lipella Pharmaceuticals Granted FDA Orphan Designation for Oral Graft-versus-Host Disease Drug](https://prismmediawire.com/wp-content/uploads/2023/11/Prowly-LIPO-1-1080x675.jpg)